Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LM011 in non-alcoholic steatohepatitis
ACTRN12619000610134Phase 2Recruiting
- Sponsor
- LifeMax Laboratories
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sirolimus in metabolic dysfunction-associated steatohepatitis (MASH), sponsored by LifeMax Laboratories. Primary endpoints: Percent change from screening in liver fat fraction by MRI-PDFF and Proportion of subjects with at least 25% decrease in liver steatosis. Started Apr 2019; status: recruiting.
02
Drugs
sirolimus
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on ACTRN12619000610134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619000610134.